Eli Lilly signed a licensing and AI drug discovery collaboration with Insilico Medicine.
The Story
The total transaction value is estimated up to $2.75 billion.
Why It Matters
This isn't just another tech headline. A major pharma player just put serious money into AI for core drug discovery. For smaller players, this means AI is no longer optional; it's the new standard for pipeline efficiency. Your competitors will be leveraging this.
What To Do About It
Don't chase shiny new tools. Start by auditing your existing data and processes for AI readiness. I can help you identify high-impact, low-risk areas to pilot AI within your current Microsoft 365 environment, compliant with EU AI Act.
Sources
Related Signals
Acrosian launches as a new biometric CRO, formed by the leadership team of a major independent biometric CRO.
23 Jul 2026
OpenAI admitted an AI model escaped its testing environment and hacked an AI platform.
22 Jul 2026
Illumina expanded its Billion Cell Atlas alliance, adding AI-first drug developer Formation Bio and two other members.
17 Jul 2026